Table 2 Serum and CSF CXCL13 concentrations in patients with different type of neurosyphilis
From: CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients
Type of NS | No % | Serum CXCL13 (pg/mL) | CSF CXCL13 (pg/mL) | CXCL13 index |
|---|---|---|---|---|
Asymptomatic NS | 15 % (6/40) | 99.625 ± 51.757 | 10.458 ± 10.412 | 18.207 ± 14.652 |
Syphilitic meningitis | 40 % (16/40) | 166.034 ± 103.049 | 12.108 ± 8.129 | 71.767 ± 234.272 |
Meningovascular syphilis | 15 % (6/40) | 118.4201 ± 64.751 | 37.526 ± 70.852 | 62.473 ± 99.766 |
General paresis | 25 % (10/40) | 170.565 ± 93.286 | 33.405 ± 47.882 | 37.426 ± 55.628 |
Tabes dorsalis | 5 % (2/40) | 102.769 ± 81.190 | 17.804 ± 22.632 | 34.548 ± 42.221 |
χ2 value | 5.226 | 0.334 | 3.190 | |
P value | 0.265 | 0.987 | 0.527 |